CoChat

Effect of renal impairment on the pharmacokinetics of the GLP‐1 analogue liraglutide

Open access
Jacobsen, Lisbeth V., Hindsberger, Charlotte, Robson, Richard, Zdravkovic, Milan · 2009 · British Journal of Clinical Pharmacology
Cited by 215

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Patients with Type 2 diabetes are likely to have or to develop renal impairment, which affects the pharmacokinetics of some antidiabetic treatments. • Whether dosing of the once‐daily human glucagon‐like peptide‐1 analogue liraglutide should be modified in patients with renal impairment has not previously been studied. WHAT THIS STUDY ADDS • Renal dysfunction was not found to increase the exposure of liraglutide. • Hence, no dose adjustment is expected to be required in patients with Type 2 diabetes and renal impairment treated with liraglutide. AIMS To investigate whether dose adjustment of the once‐daily human glucagon‐like peptide‐1 analogue liraglutide is required in patients with varying stages of renal impairment. METHODS A cohort of 30 subjects, of whom 24 had varying degrees of renal impairment and six had normal renal function, were given a single dose of liraglutide, 0.75 mg subcutaneously, and completed serial blood sampling for plasma liraglutide measurements for pharmacokinetic estimation. RESULTS No clear trend for change in pharmacokinetics was evident across groups with increasing renal dysfunction. While the between‐group comparisons of the area under the liraglutide concentration–curve (AUC) did not demonstrate equivalence [estimated ratio AUC severe/AUC healthy 0.73, 90% confidence interval (CI) 0.57, 0.94; and AUC (continuous ambulatory peritoneal dialysis)CAPD/AUC healthy 0.74, 90% CI 0.56, 0.97], the regression analysis of log(AUC) for subjects with normal renal function and mild‐to‐severe renal impairment showed no significant effect of decreasing creatinine clearance on the pharmacokinetics of liraglutide. The expected AUC ratio between the two subjects with the lowest and highest creatinine clearance in the study was estimated to be 0.88 (95% CI 0.58, 1.34) (NS). Degree of renal impairment did not appear to be associated with an increased risk of adverse events. CONCLUSIONS This study indicated no safety concerns regarding use of liraglutide in patients with renal impairment. Renal dysfunction was not found to increase exposure of liraglutide, and patients with Type 2 diabetes and renal impairment should use standard treatment regimens of liraglutide. There is, however, currently limited experience with liraglutide in patients beyond mild‐stage renal disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2125.2009.03536.x

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 215

Metadata

Authors
Jacobsen, L. V., Hindsberger, C., Robson, R., & Zdravkovic, M.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2009-11-27
Volume
68
Issue
6
Pages
898-905
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W2140536043
Cited by
215
References
8
FWCI
13.70
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of renal impairment on the pharmacokinetics of the GLP‐1 analogue liraglutide. https://app.cochat.ai/papers/10.1111/j.1365-2125.2009.03536.x
The paper
Jacobsen, L. V., Hindsberger, C., Robson, R., & Zdravkovic, M. (2009). Effect of renal impairment on the pharmacokinetics of the GLP‐1 analogue liraglutide. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2009.03536.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.